ArticleBMC cancer2022

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.

Alexander Schmitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.